Health Tidings Mergers & AcquisitionsBayer to Acquire Perfuse Therapeutics in Up to USD 2.45 Billion Ophthalmolo... Bayer to Acquire Perfuse Therapeutics in Up to USD 2.45 Billion Ophthalmolo... Read Post »
Health Tidings Mergers & AcquisitionsHalozyme Licenses Hypercon Technology to Oruka Therapeutics for ORKA-001 Halozyme Licenses Hypercon Technology to Oruka Therapeutics for ORKA-001 Read Post »
Health Tidings Mergers & AcquisitionsArrowhead Takes Aim at MASH Genetics with Madrigal Licensing Deal Arrowhead Takes Aim at MASH Genetics with Madrigal Licensing Deal Read Post »
GenericsLupin Limited Secures FDA Nod for Ravicti Generic Lupin Limited Secures FDA Nod for Ravicti Generic Read Post »
Health Tidings Mergers & AcquisitionsEvotec–Almirall Hit Preclinical Milestone for Skin Disease Therapy Evotec–Almirall Hit Preclinical Milestone for Skin Disease Therapy Read Post »
Health TidingsFDA Grants Rare Pediatric Disease Designation to Atossa’s (Z)-Endoxifen FDA Grants Rare Pediatric Disease Designation to Atossa’s (Z)-Endoxifen Read Post »
Health Tidings Mergers & AcquisitionsBioCryst and Neopharmed Gentili Sign Navenibart Deal to Support 2027 Filing BioCryst and Neopharmed Gentili Sign Navenibart Deal to Support 2027 Filing Read Post »
Health TidingsMacroGenics Expands ZYNYZ Royalty Deal with Sagard, Secures Up to $80 Milli... MacroGenics Expands ZYNYZ Royalty Deal with Sagard, Secures Up to $80 Milli... Read Post »
ManufacturingSerum Institute Starts Development of Meiji’s Japanese Encephalitis Vacci... Serum Institute Starts Development of Meiji’s Japanese Encephalitis Vacci... Read Post »
Health TidingsApotex Delivers First Canadian‑Made Generic Ozempic Equivalent to Market Apotex Delivers First Canadian‑Made Generic Ozempic Equivalent to Market Read Post »
Health TidingsNeurocrine’s CRENESSITY Delivers Two-Year Hormone Control in Pediatric CA... Neurocrine’s CRENESSITY Delivers Two-Year Hormone Control in Pediatric CA... Read Post »
Health TidingsIncyte Secures FDA Nod for Jakafi XR Extended-Release Tablets Incyte Secures FDA Nod for Jakafi XR Extended-Release Tablets Read Post »
Health TidingsVanda Launches NEREUS™ (Tradipitant) in the U.S. for Motion Sickness Rela... Vanda Launches NEREUS™ (Tradipitant) in the U.S. for Motion Sickness Rela... Read Post »
ManufacturingAREXVY Gains FDA Approval for Ready-to-Use Vial and Prefilled Syringe AREXVY Gains FDA Approval for Ready-to-Use Vial and Prefilled Syringe Read Post »
Health TidingsRevolution Medicines Secures FDA Expanded Access for Daraxonrasib in PDAC Revolution Medicines Secures FDA Expanded Access for Daraxonrasib in PDAC Read Post »
Health Tidings Mergers & AcquisitionsUCB Taps IMIDomics to Power Its Precision Medicine Engine UCB Taps IMIDomics to Power Its Precision Medicine Engine Read Post »
Health TidingsFDA Panel Votes Against AstraZeneca’s Camizestrant Combo FDA Panel Votes Against AstraZeneca’s Camizestrant Combo Read Post »
Health TidingsAstraZeneca Reports Positive FDA Panel Vote for Truqap Combination AstraZeneca Reports Positive FDA Panel Vote for Truqap Combination Read Post »
Health TidingsJohnson & Johnson Discontinues CD20 and CD19–CD20 CAR-Tv Programs in ... Johnson & Johnson Discontinues CD20 and CD19–CD20 CAR-Tv Programs in ... Read Post »
Health TidingsuniQure Moves Toward UK Approval Filing for AMT-130 in Huntington’s Disea... uniQure Moves Toward UK Approval Filing for AMT-130 in Huntington’s Disea... Read Post »
Health TidingsInsilico Medicine Advances AI-Developed Rentosertib into Inhalation Trial Insilico Medicine Advances AI-Developed Rentosertib into Inhalation Trial Read Post »
Health TidingsBayer Files Asundexian in China for Secondary Stroke Prevention Bayer Files Asundexian in China for Secondary Stroke Prevention Read Post »
Health TidingsBiogen and Eisai Strengthen LEQEMBI’s Role in Alzheimer’s Treatment Biogen and Eisai Strengthen LEQEMBI’s Role in Alzheimer’s Treatment Read Post »
Food Health Tidings Regulatory & Health PolicyWhy FDA’s Infant Formula Findings Reassure, Yet Call for Vigilance Why FDA’s Infant Formula Findings Reassure, Yet Call for Vigilance Read Post »
Health TidingsBeOne Gains Ground in GEA as FDA Fast-Tracks TEVIMBRA Combo BeOne Gains Ground in GEA as FDA Fast-Tracks TEVIMBRA Combo Read Post »
Health TidingsPfizer Extends U.S. Patent Protection for Tafamidis Drug VYNDAMAX to 2031 Pfizer Extends U.S. Patent Protection for Tafamidis Drug VYNDAMAX to 2031 Read Post »
Health Tidings Regulatory & Health PolicyMHRA and FDA Drive Changes to Improve Trial Efficiency MHRA and FDA Drive Changes to Improve Trial Efficiency Read Post »
Health TidingsQUVIVIQ Powers Idorsia Growth with Strong Sales and Expanding Clinical Evid... QUVIVIQ Powers Idorsia Growth with Strong Sales and Expanding Clinical Evid... Read Post »
Health TidingsFDA Grants Fast Track to Amyloid-Depleting Antibody Coramitug for ATTR-CM FDA Grants Fast Track to Amyloid-Depleting Antibody Coramitug for ATTR-CM Read Post »
Health TidingsGSK advances bepirovirsen with FDA priority review in hepatitis B GSK advances bepirovirsen with FDA priority review in hepatitis B Read Post »
Health TidingsFDA Takes Up Zipalertinib Application for Lung Cancer FDA Takes Up Zipalertinib Application for Lung Cancer Read Post »
Health TidingsJanux discontinues JANX008 after Phase 1a results over efficacy Janux discontinues JANX008 after Phase 1a results over efficacy Read Post »
Health TidingsGilead Completes $7.8 Billion Acquisition of Arcellx, Gains Full Control of... Gilead Completes $7.8 Billion Acquisition of Arcellx, Gains Full Control of... Read Post »
Health TidingsTerns Advances TERN-701 with FDA Breakthrough Therapy Designation in CML Terns Advances TERN-701 with FDA Breakthrough Therapy Designation in CML Read Post »
Health TidingsFDA Seeks to Withdraw TAVNEOS After Identifying Efficacy Gaps FDA Seeks to Withdraw TAVNEOS After Identifying Efficacy Gaps Read Post »
Health TidingsJohnson & Johnson Secures FDA Priority Review for IMAAVY® in wAIHA Johnson & Johnson Secures FDA Priority Review for IMAAVY® in wAIHA Read Post »
Health TidingsOncolytics Biotech Aligns with FDA on Pivotal Trial Design for Pelareorep i... Oncolytics Biotech Aligns with FDA on Pivotal Trial Design for Pelareorep i... Read Post »
Health TidingsGSK moves efimosfermin forward with dual US FDA Breakthrough and EMA PRIME ... GSK moves efimosfermin forward with dual US FDA Breakthrough and EMA PRIME ... Read Post »
Health TidingsJazz Marks FDA Acceptance, Priority Review Milestone for Zanidatamab Jazz Marks FDA Acceptance, Priority Review Milestone for Zanidatamab Read Post »
Health TidingsAbbVie Steps Beyond Infusion with SC SKYRIZI Filing in Crohn’s Disease AbbVie Steps Beyond Infusion with SC SKYRIZI Filing in Crohn’s Disease Read Post »
Health Tidings Mergers & AcquisitionsBioMarin Bolsters Its Rare Disease Portfolio Through Amicus Acquisition BioMarin Bolsters Its Rare Disease Portfolio Through Amicus Acquisition Read Post »
Health TidingsGSK stands firm on Jemperli as AnaptysBio seeks to reclaim rights GSK stands firm on Jemperli as AnaptysBio seeks to reclaim rights Read Post »
GenericsAlembic Secures USFDA Approval for Fingolimod capsules for MS Alembic Secures USFDA Approval for Fingolimod capsules for MS Read Post »
Health Tidings Mergers & AcquisitionsSun Pharma Acquires Organon in $11.75 Billion Deal Sun Pharma Acquires Organon in $11.75 Billion Deal Read Post »
Health TidingsCompass Pathways gains priority voucher, speeds COMP360 review Compass Pathways gains priority voucher, speeds COMP360 review Read Post »
Health TidingsNovartis Pulls Back Pluvicto as CHMP Raises Red Flag Novartis Pulls Back Pluvicto as CHMP Raises Red Flag Read Post »
Health TidingsGrace Therapeutics Hits CRL Wall in GTx-104 Approval Bid Grace Therapeutics Hits CRL Wall in GTx-104 Approval Bid Read Post »
Health TidingsAstellas Amends Mirabegron Deal with MSN, Secures $75 Million Upfront Astellas Amends Mirabegron Deal with MSN, Secures $75 Million Upfront Read Post »
Health Tidings Mergers & AcquisitionsAbbVie Receives FDA Complete Response Letter for TrenibotulinumtoxinE AbbVie Receives FDA Complete Response Letter for TrenibotulinumtoxinE Read Post »
Health TidingsConnect Biopharma Stays the Course as Rademikibart Meets Interim Benchmarks Connect Biopharma Stays the Course as Rademikibart Meets Interim Benchmarks Read Post »
